Marktanalyse - Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
2236 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer — Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 14

Non-Small Cell Lung Cancer Overview 15

Therapeutics Development 16

Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 18

Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 43

Non-Small Cell Lung Cancer - Pipeline Products Glance 46

Non-Small Cell Lung Cancer - Products under Development by Companies 50

Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 92

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 96

Non-Small Cell Lung Cancer - Therapeutics Assessment 387

Drug Profiles 487

Non-Small Cell Lung Cancer - Dormant Projects 2104

Non-Small Cell Lung Cancer - Discontinued Products 2139

Non-Small Cell Lung Cancer - Product Development Milestones 2153

Appendix 2169





List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016 82

Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016 83

Number of Products under Development by Companies, H2 2016 85

Number of Products under Development by Companies, H2 2016 (Contd..1) 86

Number of Products under Development by Companies, H2 2016 (Contd..2) 87

Number of Products under Development by Companies, H2 2016 (Contd..3) 88

Number of Products under Development by Companies, H2 2016 (Contd..4) 89

Number of Products under Development by Companies, H2 2016 (Contd..5) 90

Number of Products under Development by Companies, H2 2016 (Contd..6) 91

Number of Products under Development by Companies, H2 2016 (Contd..7) 92

Number of Products under Development by Companies, H2 2016 (Contd..8) 93

Number of Products under Development by Companies, H2 2016 (Contd..9) 94

Number of Products under Development by Companies, H2 2016 (Contd..10) 95

Number of Products under Development by Companies, H2 2016 (Contd..11) 96

Number of Products under Development by Companies, H2 2016 (Contd..12) 97

Number of Products under Development by Companies, H2 2016 (Contd..13) 98

Number of Products under Development by Companies, H2 2016 (Contd..14) 99

Number of Products under Development by Companies, H2 2016 (Contd..15) 100

Number of Products under Development by Companies, H2 2016 (Contd..16) 101

Number of Products under Development by Companies, H2 2016 (Contd..17) 102

Number of Products under Development by Companies, H2 2016 (Contd..18) 103

Number of Products under Development by Companies, H2 2016 (Contd..19) 104

Number of Products under Development by Companies, H2 2016 (Contd..20) 105

Number of Products under Development by Companies, H2 2016 (Contd..21) 106

Number of Products under Development by Companies, H2 2016 (Contd..22) 107

Number of Products under Development by Companies, H2 2016 (Contd..23) 108

Number of Products under Investigation by Universities/Institutes, H2 2016 109

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 110

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 111

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Development, H2 2016 114

Comparative Analysis by Unknown Stage Development, H2 2016 115

Products under Development by Companies, H2 2016 116

Products under Development by Companies, H2 2016 (Contd..1) 117

Products under Development by Companies, H2 2016 (Contd..2) 118

Products under Development by Companies, H2 2016 (Contd..3) 119

Products under Development by Companies, H2 2016 (Contd..4) 120

Products under Development by Companies, H2 2016 (Contd..5) 121

Products under Development by Companies, H2 2016 (Contd..6) 122

Products under Development by Companies, H2 2016 (Contd..7) 123

Products under Development by Companies, H2 2016 (Contd..8) 124

Products under Development by Companies, H2 2016 (Contd..9) 125

Products under Development by Companies, H2 2016 (Contd..10) 126

Products under Development by Companies, H2 2016 (Contd..11) 127

Products under Development by Companies, H2 2016 (Contd..12) 128

Products under Development by Companies, H2 2016 (Contd..13) 129

Products under Development by Companies, H2 2016 (Contd..14) 130

Products under Development by Companies, H2 2016 (Contd..15) 131

Products under Development by Companies, H2 2016 (Contd..16) 132

Products under Development by Companies, H2 2016 (Contd..17) 133

Products under Development by Companies, H2 2016 (Contd..18) 134

Products under Development by Companies, H2 2016 (Contd..19) 135

Products under Development by Companies, H2 2016 (Contd..20) 136

Products under Development by Companies, H2 2016 (Contd..21) 137

Products under Development by Companies, H2 2016 (Contd..22) 138

Products under Development by Companies, H2 2016 (Contd..23) 139

Products under Development by Companies, H2 2016 (Contd..24) 140

Products under Development by Companies, H2 2016 (Contd..25) 141

Products under Development by Companies, H2 2016 (Contd..26) 142

Products under Development by Companies, H2 2016 (Contd..27) 143

Products under Development by Companies, H2 2016 (Contd..28) 144

Products under Development by Companies, H2 2016 (Contd..29) 145

Products under Development by Companies, H2 2016 (Contd..30) 146

Products under Development by Companies, H2 2016 (Contd..31) 147

Products under Development by Companies, H2 2016 (Contd..32) 148

Products under Development by Companies, H2 2016 (Contd..33) 149

Products under Development by Companies, H2 2016 (Contd..34) 150

Products under Development by Companies, H2 2016 (Contd..35) 151

Products under Development by Companies, H2 2016 (Contd..36) 152

Products under Development by Companies, H2 2016 (Contd..37) 153

Products under Development by Companies, H2 2016 (Contd..38) 154

Products under Development by Companies, H2 2016 (Contd..39) 155

Products under Development by Companies, H2 2016 (Contd..40) 156

Products under Development by Companies, H2 2016 (Contd..41) 157

Products under Investigation by Universities/Institutes, H2 2016 158

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 159

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 160

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 161

Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 162

Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2016 163

Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2016 164

Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016 165

Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 166

Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2016 167

Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 168

Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2016 169

Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 170

Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 171

Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2016 172

Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 173

Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2016 174

Non-Small Cell Lung Cancer - Pipeline by Almac Discovery Ltd, H2 2016 175

Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2016 176

Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2016 177

Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016 178

Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 179

Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2016 180

Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 181

Non-Small Cell Lung Cancer - Pipeline by APO-T BV, H2 2016 182

Non-Small Cell Lung Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 183

Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 184

Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2016 185

Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 186

Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 187

Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016 188

Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2016 189

Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2016 190

Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 191

Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2016 192

Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016 193

Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016 194

Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 195

Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016 196

Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 197

Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2016 198

Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 199

Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 200

Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2016 201

Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 202

Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 203

Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2016 204

Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 205

Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2016 206

Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016 207

Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2016 208

Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016 209

Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 210

Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 211

Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 212

Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2016 213

Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2016 214

Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2016 215

Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016 216

Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2016 217

Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016 218

Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2016 219

Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220

Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221

Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222

Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 223

Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2016 224

Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2016 225

Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 226

Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 227

Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016 228

Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016 229

Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016 230

Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 231

Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 232

Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2016 233

Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 234

Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 235

Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 236

Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016 237

Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H2 2016 238

Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2016 239

Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 240

Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 241

Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242

Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 243

Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 244

Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 245

Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp, H2 2016 246

Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H2 2016 247

Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 248

Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016 249

Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 250

Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2016 251

Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2016 252

Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 253

Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2016 254

Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc, H2 2016 255

Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2016 256

Non-Small Cell Lung Cancer - Pipeline by DormaTarg Inc, H2 2016 257

Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 258

Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 259

Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H2 2016 260

Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc, H2 2016 261

Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2016 262

Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 263

Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016 264

Non-Small Cell Lung Cancer - Pipeline by Endocyte Inc, H2 2016 265

Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2016 266

Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2016 267

Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2016 268

Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2016 269

Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2016 270

Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2016 271

Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 272

Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2016 273

Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016 274

Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corp, H2 2016 275

Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2016 276

Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 277

Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 278

Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2016 279

Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2016 280

Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2016 281

Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2016 282

Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 283

Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2016 284

Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016 285

Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2016 286

Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 287

Non-Small Cell Lung Cancer - Pipeline by Globeimmune Inc, H2 2016 288

Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2016 289

Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2016 290

Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 291

Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2016 292

Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2016 293

Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 294

Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 295

Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2016 296

Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016 297

Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2016 298

Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016 299

Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2016 300

Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2016 301

Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016 302

Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 303

Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2016 304

Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 305

Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2016 306

Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2016 307

Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 308

Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2016 309

Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2016 310

Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2016 311





List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016 82

Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016 83

Number of Products under Development by Companies, H2 2016 84

Number of Products under Investigation by Universities/Institutes, H2 2016 109

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Products, H2 2016 114

Assessment by Monotherapy Products, H2 2016 453

Assessment by Combination Products, H2 2016 454

Number of Products by Top 10 Targets, H2 2016 455

Number of Products by Stage and Top 10 Targets, H2 2016 455

Number of Products by Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Top 10 Routes of Administration, H2 2016 549

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 549

Number of Products by Top 10 Molecule Types, H2 2016 551

Number of Products by Stage and Top 10 Molecule Types, H2 2016 551

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus